Ascletis Pharma Presents Preclinical Results for Weight Management Drugs at ObesityWeek 2026

MT Newswires Live
昨天

Ascletis Pharma (HKG:1672) presented key preclinical results for ASC48, ASC30_48 fixed dose combination, and ASC37 at ObesityWeek 2026, a Monday bourse filing showed.

The two poster presentations feature in vitro activity and oral pharmacokinetics of ASC48; weight loss data for ASC30_48; and extended pharmacokinetics, in vitro insulin secretion activity, and weight-loss activity of ASC37.

ObesityWeek 2026 is being held in Washington, DC, from Nov. 14 to 17.

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10